Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System.Overweight and Obesity: Obesity Trends: U.S. Obesity Trends 1985-2004. http://www.cdc.gov/nccdphp/dnpa/obesity/trend/maps/. Accessed February 6, 2007.
2.
Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289:76-79.
3.
American Heart Association. Heart Disease and Stroke Statistics - 2005Update. Dallas, TX : American Heart Association; 2005.
4.
National Heart, Lung, and Blood Institute Obesity Education Initiative.The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health; 2000. NIH publication 00-4084. http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_b.pdf. Accessed February 6, 2007.
5.
Lyon CJ, Law RE, Hsueh WAMinireview: adiposity, inflammation, and atherogenesis. Endocrinology . 2003;144:2195-2200.
6.
Trayhurn P., Wood ISAdipokines: inflammation and the pleiotropic role of white adipose tissue . Br J Nutr. 2004;92:347-355.
7.
Després JP, Lemieux I.Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-887.
8.
Eckel RH, Kahn R., Robertson RM, Rizza RAPreventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation. 2006;113:2943-2946; Diabetes Care. 2006;29:1697-1699.
9.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26(suppl 1):S5-S20.
10.
McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005; 28:385-390.
11.
Van Gaal LF , Rissanen AM, Scheen AJ, et al; RIO-Europe Study Group.Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet.2005;365:1389-1397.
12.
Després JP, Golay A., Sjöström L.; Rimonabant in Obesity Study Group.Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia . N Engl J Med. 2005;353: 2121-2134.
13.
Pi-Sunyer FX , Aronne LJ, Heshmati HM, et al; RIO-North America Study Group.Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA.2006;295:761-775.
14.
Scheen AJ, Finer N., Hollander P., et al; RIO-Diabetes Study Group.Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660-1672.
15.
Rosenstock J.Study evaluating rimonabant efficacy in drug-naive diabetic patients. Paper presented at: the International Diabetes Federation 19th World Diabetes Congress; December 3-7, 2006; Cape Town, South Africa.
